BioSpace News Archive

Biotech Bay

Cerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional Shares

Cerus today announced the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the underwriter’s option to purchase additional shares.

February 2, 2018

·

3 min read

Drug Development

Clene Nanomedicine Announces Preclinical Results of A Novel Gold Nanocrystal Remyelinating Treatment for Multiple Sclerosis at ACTRIMS Forum Annual Meeting

Statistically significant improvements in remyelination were demonstrated via quantitation of myelin using immunohistochemistry and transmission electron microscopy.

February 2, 2018

·

3 min read

Genetown

Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) With an Exercise Price of $14.78

Akebia granted nine newly-hired employees options to purchase an aggregate of 53,550 shares of Akebia’s common stock on January 31, 2018, as inducements material to each such employee’s entering into employment with Akebia.

February 2, 2018

·

1 min read

Business

Titan Announces Amendment to Horizon Loan Agreement

Pursuant to this amendment, Titan will prepay $3M of the outstanding $7M principle amount, with an additional $1M prepayment due on the earlier of.

February 2, 2018

·

3 min read

Policy

AstraZeneca Drops Phase III Asthma Drug as Company Posts Disappointing 2017 Financials

Failing numbers are putting a strain on CEO Pascal Soriot’s pledge of achieving $45B of annual revenue by 2023.

February 2, 2018

·

2 min read

·

Alex Keown

Business

Amgen to Build New $300M Facility After Tax Changes

Amgen is expected to add 220 jobs to the local economy and employ up to 300 full-time employees.

February 2, 2018

·

2 min read

·

Mark Terry

Roche Could Take a $500M Hit Over Patent Losses

Deals

M&A Chatter Swirls Over Amgen’s $70B Cashpile

Amgen reported its fourth-quarter financials yesterday, but in anticipation of this year’s hot merger-and-acquisition market, a lot of focus has been on the company’s considerable available cash.

February 2, 2018

·

2 min read

·

Mark Terry